Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment

The BCR/ABL tyrosine kinase inhibitor imatinib mesylate is highly effective in the treatment of chronic myelogenous leukemia (CML) but fails to eliminate all leukemia cells. Residual leukemia stem and progenitor cells persist in imatinib-responsive patients and may be a potential source of relapse....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2007-02, Vol.67 (3), p.1113-1120
Hauptverfasser:	HOLTZ, Melissa, FORMAN, Stephen J, BHATIA, Ravi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antineoplastic agents Apoptosis - drug effects Benzamides Biological and medical sciences Cell Growth Processes - drug effects Female Hematologic and hematopoietic diseases Humans Imatinib Mesylate Intercellular Signaling Peptides and Proteins - pharmacology Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Neoplastic Stem Cells - drug effects Neoplastic Stem Cells - pathology Pharmacology. Drug treatments Piperazines - pharmacology Pyrimidines - pharmacology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!